CLOs on the Move

BiOptix

www.bioptix.com

 
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bioptix.com
  • 1775 38th Street
    Boulder, CO USA 80301
  • Phone: 303.545.5550

Executives

Name Title Contact Details

Similar Companies

SangStat Medical Corporation

SangStat Medical Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Seattle Institute for Biomedical and Clinical Research

Seattle Institute for Biomedical and Clinical Research is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NTX

Nature`s Toolbox™ is a Santa Fe-based R&D, bioinformatics and biomanufacturing start-up that developed a unique, recombinant in vitro transcription/translation system for research- to mid-scale, host-independent biological manufacturing.

Bellen Health Care System

Bellen Health Care System is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.